Adial Pharmaceuticals Stock News

CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve

Adial Pharmaceuticals (NASDAQ:ADIL) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The []

CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received the balance of $720,000 due from the $800,000 private placement previously disclosed by the Company on November 10, 2021 (the “Offering”). The shares of common stock sold in the Offering were priced at $4.00 per share and a total of 200,000 shares (the “Shares”) were purchased in the Offering. The Offering was fully subscribed.

Zacks Investment Research lowered shares of Adial Pharmaceuticals (NASDAQ:ADIL) from a buy rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. According to Zacks, Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. []

Zacks Investment Research upgraded shares of Adial Pharmaceuticals (NASDAQ:ADIL) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $3.00 price target on the stock. According to Zacks, Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the [] The post Adial Pharmaceuticals (NASDAQ:ADIL) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .

Analysts expect that Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) will post earnings per share (EPS) of ($0.21) for the current quarter, according to Zacks. Zero analysts have provided estimates for Adial Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.21). Adial Pharmaceuticals reported earnings of ($0.24) per []

Geode Capital Management LLC raised its stake in Adial Pharmaceuticals, Inc. by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the

Geode Capital Management LLC raised its stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,246 shares of the companys stock after acquiring an additional 10,261 shares during the quarter. Geode Capital Management [] The post Geode Capital Management LLC Buys 10,261 Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) appeared first on ETF Daily News .

PNV2 demonstrates reduction of metastases in animal model PNV2 demonstrates reduction of metastases in animal model

CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments.

Adial Pharmaceuticals (NASDAQ:ADIL) released its quarterly earnings results on Sunday. The company reported ($0.22) EPS for the quarter, hitting the Zacks consensus estimate of ($0.22), Fidelity Earnings reports. ADIL traded up $0.03 during trading on Tuesday, hitting $3.19. 195,402 shares of the stock traded hands, compared to its average volume of 702,662. The firm has []

Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound fo

CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therap

CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve

Data merits further testing for pain reduction as a possible alternative to opioids